WA-KYMETA
2.12.2020 10:36:09 CET | Business Wire | Press release
Kymeta (www.kymetacorp.com )—the communications company making mobile global—announced that the Kymeta™ u8 and Kymeta Connect™ are available for government and commercial purchase after November 30, 2020, unlocking the potential of broadband satellite connectivity and cellular networks to satisfy the overwhelming demand for communications on the move.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201130005022/en/
Kymeta’s next-generation solutions are built for mobility and designed to meet the needs of global defense agencies, government, first responders, and commercial customers. Kymeta’s products and services have been field deployed for three years and the demand for the Kymeta u8 presales has already exceeded expectations. With the introduction of the Kymeta u8, the company has meaningfully increased antenna throughput and significantly reduced the total cost of ownership. Kymeta’s new products and services offer a breakthrough in performance, ease of use, and affordability, and it anticipates that these solutions will further enhance its position in both commercial and government markets, further increasing its lead over competitive offerings.
“Government and military need the most reliable and seamless connectivity to safely fulfill their missions,” said Walter Berger, Kymeta President, and COO. “These men and women often go to the most remote or disaster-stricken areas of the world, and they need reliable communications to rescue lives, keep property safe, and complete missions. Our government, military, and commercial customers trust Kymeta solutions. The enhanced performance of the u8 is helping our customers make fast, easy, and reliable mission-critical communications on the move a reality.”
The launch of Kymeta’s next-generation solutions builds on the successful deployment of our beta program earlier this year to facilitate real-world testing. The testing demonstrated throughputs of over 45Mbps in land mobile environment with large scan-off angles of over 50 degrees, which is a remarkable achievement for such a low power (<150W) electronically steered antenna platform. The u8 was tested in regions around the world including North America, APAC, and Europe, in a variety of conditions confirming that the product can be operated with confidence even under the most trying scenarios.
“My team works in some of the most densely populated, rugged, and steep forest terrain in the U.S.,” said Tim Dunfee, Deputy Forest Fire Chief, U.S. Forest Service. “There are places across our varied terrain that have been engulfed by fires and communications cell towers that have been destroyed, causing loss of all communications. When we tested Kymeta’s solutions, we could use FaceTime and make voice calls for the first time. We now have a Kymeta antenna installed on one of our vehicles and deploy it to every forest fire because we know it has reliable communications wherever it goes.”
The Kymeta u8 covers the full Ku-band and is designed to be LEO upgradeable. The u8 is available as an antenna, an ODU (with no modem), and a turnkey terminal with embedded satellite modem, cellular modem, and SD-WAN capabilities. The Kymeta terminals are easy to set up and they acquire service within minutes of being powered. Also coming soon is a transportable configuration called the u8 GO, which is ideal for rapid deployments. The u8 GO will enable safe transport with a hardened case for protection and provides a built-in car mount to support easy operations on the pause and on the move.
Combining the u8 with Kymeta’s hybrid satellite-cellular connectivity services, Kymeta Connect transforms the purchase and consumption of mobile data delivering a complete end-to-end solution with a best-in-industry customer experience. The all-inclusive hybrid satellite-cellular connectivity, global support, and network services package start at $999 per month.
Kymeta Connect is powered by a virtual architecture consisting of an operational stack that connects remote terminals to managed satellite and cellular services, integrates a state-of-the-art digital back office for service and subscription management, and includes an operations and care element to deliver an excellent customer experience. These services are augmented with a unique application called Access which simplifies the control, management, and monitoring of all hardware and connectivity solutions. The newly announced app is available for download through the Apple and Google Play stores. Today, Kymeta Access can be used on a tablet or through a web-based portal to interact with hardware, data, customer care, and subscription services.
Kymeta expects to further accelerate its new product development and commercialization of its next-generation solutions and looks forward to sharing more in 2021.
About Kymeta
Kymeta is unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for comms on the move and making mobile global. Lepton Global Solutions, a Kymeta company, hosts the company’s satellite connectivity solutions and offers unique, complete, and turnkey bundled solutions to the market based on best in class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta Connect™ services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005022/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom